A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

Trial Profile

A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs Sapacitabine (Primary) ; Seliciclib (Primary)
  • Indications Advanced breast cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 14 May 2018 According to a Cyclacel Pharmaceuticals media release, he company is planning to share updated mature data from the part 1 extension of this trial and complete part 3 enrollment in 2018.
    • 21 Feb 2018 According to a Cyclacel Pharmaceuticals media release, the extension part of this study enrolled 20 patients and is in a follow-up stage. Part 3 of this study has been open for enrolment.
    • 09 Jan 2018 According to a Cyclacel Pharmaceuticals media release, company plans to update mature data from part 1 extension DDR study and complete part 3 in study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top